Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Indian variant

- PMLiVE

Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO

Nuvaxovid XBB.1.5 is now approved for emergency use in all 194 WHO member states

- PMLiVE

AstraZeneca’s rare disease unit receives NICE recommendation for Wolman disease therapy in infants

The enzyme replacement therapy will become the first treatment available on the NHS for the rare genetic disease

- PMLiVE

AstraZeneca gains rights to Usynova’s KRAS inhibitor in deal worth almost $420m

There are currently no approved drugs specifically targeting the KRAS G12D mutation

- PMLiVE

AstraZeneca announces launch of new healthtech business Evinova to optimise clinical trials

Evinova aims to meet the needs of patients, healthcare professionals and regulators

- PMLiVE

Pfizer and Astellas’ Xtandi approved by FDA for earlier prostate cancer indication

Xtandi is the first androgen receptor signalling inhibitor approved for this patient population

- PMLiVE

AstraZeneca’s Truqap plus Faslodex receives FDA approval for advanced breast cancer

About 290,000 people in the US will be diagnosed with breast cancer in 2023

- PMLiVE

AstraZeneca shares positive phase 3 results for Imfinzi combination in liver cancer

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

- PMLiVE

AstraZeneca gains rights to Eccogene’s cardiometabolic disease drug in deal worth over $1.8bn

The oral candidate could offer more dosing convenience over current injectable therapies

- PMLiVE

Researchers improve understanding of COVID-19 virus and future variants

The study aims to contribute to the design of future COVID-19 vaccines and drugs

- PMLiVE

BioNTech acquires right to Biotheus’ bispecific antibody candidate in deal worth over $1bn

PM8002 is currently being evaluated in phase 2 studies in patients with advanced solid tumours

- PMLiVE

Pfizer’s Litfulo approved by MHRA for adults and adolescents with alopecia areata

The autoimmune disease affects approximately 147 million people globally

- PMLiVE

AstraZeneca and Cellectis enter gene therapy partnership worth over $2.2bn

The deal gives AZ access to Cellectis’ gene editing technologies and manufacturing capabilities

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links